Trial · NCT03649607
Accelerated Resolution Therapy for HIV Positive African, Caribbean and Black
NCT03649607, Not applicable, Unknown, Unity Health Toronto
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Accelerated Resolution Therapy for HIV Positive African, Caribbean and Black. Trials, record NCT03649607. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03649607
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Accelerated Resolution Therapy for HIV Positive African, Caribbean and Black
- NCT number
- NCT03649607
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Unity Health Toronto
- Conditions
- HIV, Post Traumatic Stress Disorder
- Interventions
- Accelerated Resolution Therapy
- First posted
- 2018-08-28
- Last updated
- 2019-04-10
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | HIV Symptom Distress Scale (SDS). | Symptom distress score 60 days post the study start date. | This 20-item instrument is used to measure overall HIV symptom frequency, distress and clinically relevant clusters. Participants are asked to indicate which of the 20 symptoms they have experienced in the past 2 weeks. Participants are then asked to rate symptom that are present, on the extent to which the symptoms are bothersome (0=do not have symptom; 25=have symptom, but no bother; 50=have symptom, little bother; 75=have symptom, bothers me some; 100= have symptom, bothers me a lot). Scores range from 0 to 100. Higher scores indicate greater symptom distress. |
| Secondary | HIV Associated Neurocognitive Disease (HAND). | Composite Z-score 60 days post the study start date. | The HAND assessment includes a battery of measures commonly used to evaluate neurocognitive functioning in 6 domains: executive function, speed of information processing, attention and working memory, and learning memory. The neurocognitive evaluation will be performed by trained staff and supervised by Dr. Adwoa Agyei with consultation from Dr. Giovanni Schifitto. The assessment will include tests of: * Executive Function using "Trailmaking Test Part B, Stroop Interference task" * Speed of Information Processing using "Symbol Digit Modalities Test and Stroop Color Naming" * Attention Memory using "CalCAP(CRT4) and WAIS-III Letter-Number Sequencing" |
| Secondary | Working and learning memory | Composite Z-score 60 days post the study start date. | Patient's learning and working memory will be assessed using the following tests: Rey Complex Figure Test Immediate Recall, Rey Auditory Verbal Learning, Test RAVLT Delayed Recall, Rey Complex Figure Test Delayed Recall. The working and memory test will be part of the HAND assessment. |
| Other | HIV Viral Load | Number of viral particles per ml of plasma 60 days post the study start date. | The investigators will assess the volume of HIV in serum measured using reverse transcriptase polymerase chain reaction (RT PCR). The HIV viral load is a measure of the number of viral particles per ml of plasma. Higher numbers of HIV viral copies indicate inadequate viral suppression and insufficient immune function. The data will be entered directly into REDCap by the St. Michael's Hospital lab personnel. The investigators will code viral suppression as \<50 HIV copies/mL of blood as "=yes" and ≥50 "=no." |
| Other | Post Traumatic Stress Disorder (PTSD) Checklist - Civilian Version (PCL-5) | Posttraumatic stress score 60 days post the study start date. | This 20-item measure assesses symptoms of posttraumatic stress. It assesses an individual's symptoms based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for PTSD. The PCL-5 focuses on four aspects of distressing memories: re-experiencing the event, avoidance, mitigation and hyperarousal. The scale uses a 5-point Likert scale that ranges from 0 to 4 (0 \[Not at all\]; 1\[A little bit\]; 2 \[Moderately\]; 3 \[Quite a bit\]; 4 \[Extremely\]) to rate each of the 20 items on the degree to which symptoms were present and bothersome in the prior 30-days. For PTSD diagnosis, the score must be above certain cut-point indicating moderate to high symptom severity. The PCL-5 showed good internal consistency in a study with HIV-positive patients in Ghana (α=0.79). |
| Other | HIV/AIDS Related Quality of Life | Quality of life measure 60 days post the study start date. | There is a 34-item tool that measures experiences in overall function, life satisfaction, health and financial worries, worries about medication, HIV disclosure, living with HIV and doctor satisfaction in the past month. Check boxes to 5 specific answers (All the time; A lot of the time; Some of the time; A little of the time; None of the time) are used to measure and evaluate quality of life. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Complex Figure Copy and Recall | Secondary outcome | ConductCognition |
| Letter-Number Sequencing Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03649607
GET https://conductscience.org/api/trials/v1/NCT03649607/registered